Multicentre development and validation of a risk model integrating immunotherapy and coagulation biomarkers for thrombosis in autoimmune neurological disorders.

PURPOSE: Patients with Autoimmune Neurological Disorders (ANDs) require routine immunomodulatory therapy, which inherently increases thrombosis risk. Despite this recognised association, reliable tools for thrombosis prediction remain limited, highlighting the need for accurate risk stratification to inform targeted prevention strategies.

PATIENTS AND

METHODS

This multicentre retrospective study developed a machine learning-based thrombosis risk prediction model using data from 786 patients with ANDs receiving immunomodulatory therapy. The model was trained on data from three centres and externally validated on an independent fourth centre, evaluating six algorithms based on the area under the receiver operating characteristic curve (AUROC), area under the precision-recall curve (AUPRC), and Brier score. Feature selection and Shapley Additive Explanations (SHAP) analysis were applied to ensure model interpretability.

RESULTS

Among all algorithms tested, XGBoost (XGB) demonstrated the best performance. On the external validation set, the XGB model achieved an AUROC of 0.949, AUPRC of 0.544, and Brier score of 0.045, significantly outperforming the traditional Padua score. SHAP analysis identified the top three thrombotic risk factors: elevated D-dimer levels, prolonged immobilisation, and advanced age. The total doses of intravenous immunoglobulin and glucocorticoid were also confirmed as significant contributors. The model further enabled stratification into low-, intermediate-, and high-risk groups, offering a practical tool for individualised thromboprophylaxis.

CONCLUSION

This study presents a high-performing, interpretable model for early thrombosis risk prediction in patients with ANDs, which facilitates timely clinical decision-making and targeted preventive strategies to reduce thromboembolic complications.